Budget Impact Analysis of the Incorporation of Mechanical Thrombectomy with Stent Retrievers after Thrombolysis in Ischemic-Stroke with Large Vessel Occlusion in Programa De Atencion medica Integral Pami in Argentina.
Author(s)
Lylyk P1, Cirio J2, Toranzo C3, Aiello EC4, Paredes D5, Valencia J6
1General Director and CEO, ENERI (Equipo de Neurocirugía Endovascular y Radiología Intervencionista) and Clínica La Sagrada Familia, Buenos Aires, Argentina, 2Chairman of the Acute Stroke Unit, Clínica La Sagrada Familia, Chairman of the Department of Neurology, ENERI, CAPITAL FEDERAL, B, Argentina, 3General Manager ENERI (Equipo de Neurocirugía Endovascular y Radiología Intervencionista) and Clínica La Sagrada Familia, Buenos Aires, Argentina, 4Independent Consultant, Buenos Aires, Argentina, 5Medtronic Senior Health Policy Specialist - Health Economics & Reimbursement, Santiago, RM, Chile, 6Medtronic, Miami, FL, USA
OBJECTIVES : Stroke is responsible for mortality and long-term disability in Argentina. Available treatments for stroke due to Large Vessel Occlusion (LVO) are Thrombolysis (IV-tPA) and Mechanical Thrombectomy (MT). However, despite its clinical benefits, MT coverage in Argentina and PAMI is low. A Budget-Impact Analysis (BIA) was conducted to estimate the financial impact of incorporating MT after IV-TPA in PAMI for the elderly. METHODS : A BIA was carried-out based on a 6-step approach and a static model, from the PAMI perspective. The patient population was identified based on a funnel of medical criteria and local epidemiological data, for a lifetime horizon. The current and future treatment mix was identified based on manufacturer data and expert consultations. Costs were estimated from “módulos” in Argentinian pesos for acute and long-term phases, and changes in disease-related costs were calculated. Two scenarios were tested: with a staggering growth of 40% in procedures in 5 years and without growth in current MT procedures (15% of coverage). RESULTS : The analysis showed that the scenario of increased access to MT begins to show savings (-0,02%) when compared to the scenario of maintained access after two years (AR$9.749.400.581versus AR$9.747.850.230). Financial savings derived from greater access to MT in the eligible population are observed in the third (AR$-187.310.897; -1,48%), fourth (AR$-504.162.548; -3,21%) and fifth year (AR$-958,029,266; -5,10%). In the fifth year, , 2.624 patients would have been treated at savings of -2,35% (AR$-1.592.084.696) in the scenario with increased MT access, instead of 984 cases at a greater financial impact. CONCLUSIONS : The incremental costs of the device are offset by the costs of other categories (hospitalization and long-term costs). However, more patients are treated with a therapy that in the short term is more expensive than current alternatives, the better results of the patient result in avoiding the expense of worse levels of disability and illness.
Conference/Value in Health Info
2021-05, ISPOR 2021, Montreal, Canada
Value in Health, Volume 24, Issue 5, S1 (May 2021)
Code
PND36
Topic
Economic Evaluation, Epidemiology & Public Health
Topic Subcategory
Budget Impact Analysis, Public Health
Disease
Neurological Disorders
Explore Related HEOR by Topic